HK1050217A1 - Clearance of neoplastic cells from mixed cellular compositions using viruses - Google Patents

Clearance of neoplastic cells from mixed cellular compositions using viruses

Info

Publication number
HK1050217A1
HK1050217A1 HK03102325.9A HK03102325A HK1050217A1 HK 1050217 A1 HK1050217 A1 HK 1050217A1 HK 03102325 A HK03102325 A HK 03102325A HK 1050217 A1 HK1050217 A1 HK 1050217A1
Authority
HK
Hong Kong
Prior art keywords
viruses
clearance
neoplastic cells
cellular compositions
mixed cellular
Prior art date
Application number
HK03102325.9A
Other languages
English (en)
Inventor
Donald Morris
Bradley G Thompson
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of HK1050217A1 publication Critical patent/HK1050217A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12241—Use of virus, viral particle or viral elements as a vector
    • C12N2720/12243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03102325.9A 2000-05-03 2003-04-01 Clearance of neoplastic cells from mixed cellular compositions using viruses HK1050217A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20199000P 2000-05-03 2000-05-03
US20538900P 2000-05-19 2000-05-19
US26805401P 2001-02-13 2001-02-13
US27678201P 2001-03-16 2001-03-16
PCT/CA2001/000609 WO2001083710A2 (fr) 2000-05-03 2001-05-01 Clairance virale de cellules neoplastiques de compositions cellulaires mixtes

Publications (1)

Publication Number Publication Date
HK1050217A1 true HK1050217A1 (en) 2003-06-13

Family

ID=27498447

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03102325.9A HK1050217A1 (en) 2000-05-03 2003-04-01 Clearance of neoplastic cells from mixed cellular compositions using viruses

Country Status (14)

Country Link
US (3) US20010048919A1 (fr)
EP (1) EP1278823B1 (fr)
JP (2) JP4509455B2 (fr)
AR (1) AR028040A1 (fr)
AT (1) ATE517983T1 (fr)
AU (2) AU5807701A (fr)
BR (1) BR0110481A (fr)
CA (1) CA2408251C (fr)
DK (1) DK1278823T3 (fr)
HK (1) HK1050217A1 (fr)
IL (1) IL152391A (fr)
MX (1) MXPA02010743A (fr)
NZ (1) NZ522180A (fr)
WO (1) WO2001083710A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
CA2412493C (fr) 2000-06-26 2010-11-09 Wellstat Biologics Corporation Elimination de cellules a l'aide de virus
KR100492017B1 (ko) * 2002-06-24 2005-05-30 학교법인고려중앙학원 인간 간엽줄기 세포를 이용한 항암치료방법
US20050214266A1 (en) * 2004-03-12 2005-09-29 Oncolytics Biotech Inc. Combination of transplantation and oncolytic virus treatment
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP1917351A4 (fr) 2005-08-01 2009-12-16 Univ Technologies Int Réovirus atténué
DE202006020393U1 (de) 2006-12-12 2008-07-17 Labes, Holger Handschelle
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US9623096B2 (en) * 2011-11-09 2017-04-18 Celverum Inc. Virally infected hematopoietic cells and uses thereof
CN110117577B (zh) * 2018-02-05 2023-10-24 中国科学院武汉物理与数学研究所 低毒单纯疱疹病毒系统及其构建方法和应用
KR102141496B1 (ko) * 2018-04-27 2020-08-06 한국화학연구원 투명화된 거대조직의 면역염색용 조성물 및 이를 이용한 투명화된 거대 생체 조직의 면역염색 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1221307A (fr) * 1982-12-02 1987-05-05 Nobutaka Tani Adsorbent en methode de preparation
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
JPH09506866A (ja) * 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
US5514340A (en) * 1994-01-24 1996-05-07 Magnetix Biotechnology, Inc. Device for separating magnetically labelled cells
WO1995032300A1 (fr) * 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Destruction biologique selective des cellules tumorales
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5840502A (en) * 1994-08-31 1998-11-24 Activated Cell Therapy, Inc. Methods for enriching specific cell-types by density gradient centrifugation
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6475481B2 (en) * 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO2000012103A1 (fr) * 1998-08-31 2000-03-09 Ambrus Julian L Procede d'elimination du sang de virus hiv et d'autres virus
EP1227828A1 (fr) * 1999-11-12 2002-08-07 Oncolytics Biotech, Inc. Virus pour le traitement des troubles de la proliferation cellulaire
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
CA2412493C (fr) * 2000-06-26 2010-11-09 Wellstat Biologics Corporation Elimination de cellules a l'aide de virus
WO2005007824A2 (fr) * 2003-07-08 2005-01-27 Arizona Board Of Regents Mutants du virus vaccine tenant lieu d'agents oncolytiques

Also Published As

Publication number Publication date
EP1278823B1 (fr) 2011-07-27
DK1278823T3 (da) 2011-09-05
IL152391A (en) 2010-11-30
WO2001083710A3 (fr) 2002-05-02
IL152391A0 (en) 2003-05-29
NZ522180A (en) 2004-11-26
WO2001083710A2 (fr) 2001-11-08
JP4509455B2 (ja) 2010-07-21
AU5807701A (en) 2001-11-12
JP2003531605A (ja) 2003-10-28
EP1278823A2 (fr) 2003-01-29
CA2408251C (fr) 2008-01-22
BR0110481A (pt) 2003-04-08
AU2001258077B2 (en) 2006-07-20
CA2408251A1 (fr) 2001-11-08
JP2008283982A (ja) 2008-11-27
MXPA02010743A (es) 2003-05-14
US20050026289A1 (en) 2005-02-03
US20010048919A1 (en) 2001-12-06
US20080038822A1 (en) 2008-02-14
AR028040A1 (es) 2003-04-23
ATE517983T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
HUP0302922A3 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them
PL359064A1 (en) Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
AU2495400A (en) Surfactant compositions containing alkoxylated amines
SG117450A1 (en) Cement admixture and cement composition
AU6448101A (en) Novel compositions of minoxidil
HK1039110A1 (zh) 以新穎的合成物及組分作為蛋白酶抑制劑
EP1389970A4 (fr) Compositions et methodes permettant un double ciblage d'infections virales et de cellules cancereuses
HK1050217A1 (en) Clearance of neoplastic cells from mixed cellular compositions using viruses
GB2370841B (en) High solid paint compositions
AU2002338709A1 (en) Workability-improving agents for cement compositions
IL152390A0 (en) Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions
EP1509539A4 (fr) Compositions et procedes concernant le cancer
EP1469769A4 (fr) Nouvelles compositions et methodes contre le cancer
GB0000187D0 (en) Chemical compositions II
EP1469870A4 (fr) Nouvelles compositions et methodes pour le traitement du cancer
ZA200208733B (en) Clearance of neoplastic cells from mixed cellular compositions using viruses.
GB0000186D0 (en) Chemical compositions I
GB0120699D0 (en) An admixture for cementitious compositions
TWI319005B (en) Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions
EP1397577A4 (fr) Compositions de ciment de faible densite pour puits
GB2372334B (en) Chemical amplifying type positive resist compositions
GB0031267D0 (en) Novel compositions
MXPA03001440A (es) Compuestos de trioxepano novedosos.
GB9924973D0 (en) Preparation of cellular components that are substantially free of chromosomal DNA
GB2379664B (en) High solid paint compositions

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20210430